For patients treated for an R/R AML, the CRc rates with single-agent FLT3 TKI versus FLT3 TKI-based combinations in first FLT3i exposure were 34% versus 53%, respectively, and those with single-agent FLT3 TKI versus FLT3 TKI-based combinations in second/third/fourth sequential FLT3 TKI exposures were 13% versus 25%, respectively. The gene discussed is FLT3; the disease is acute myeloid leukemia.